Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Tatyana A. Grushko"'
Publikováno v:
BioTechniques, Vol 39, Iss 3, Pp 316-320 (2005)
Externí odkaz:
https://doaj.org/article/3dee6f5ee3b8469d9b188cdcd6f83dd7
Autor:
Ashley A Hardeman, Yoo Jane Han, Tatyana A Grushko, Jeffrey Mueller, Maria J Gomez, Yonglan Zheng, Olufunmilayo I Olopade
Publikováno v:
PLoS ONE, Vol 17, Iss 6, p e0268693 (2022)
Maternal embryonic leucine-zipper kinase (MELK) regulates cell cycle progression and is highly expressed in many cancers. The molecular mechanism of MELK dysregulation has not been determined in aggressive forms of breast cancer, such as triple negat
Externí odkaz:
https://doaj.org/article/b7d9e314a3ee46559e693fba6ad190a7
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy.
Autor:
Obiageli Ezewuiro, Tatyana A Grushko, Masha Kocherginsky, Mohammed Habis, Jean A Hurteau, Kathryn A Mills, Jessica Hunn, Olufunmilayo I Olopade, Gini F Fleming, Iris L Romero
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0147145 (2016)
There is increasing evidence that metformin, a commonly used treatment for diabetes, might have the potential to be repurposed as an economical and safe cancer therapeutic. The aim of this study was to determine whether stage III-IV or recurrent endo
Externí odkaz:
https://doaj.org/article/bd820adbee604921aa45a8094b5ac95a
Autor:
Ashley A. Hardeman, Yoo Jane Han, Tatyana A. Grushko, Jeffrey Mueller, Maria J. Gomez, Yonglan Zheng, Olufunmilayo I. Olopade
Publikováno v:
PloS one. 17(6)
Maternal embryonic leucine-zipper kinase (MELK) regulates cell cycle progression and is highly expressed in many cancers. The molecular mechanism of MELK dysregulation has not been determined in aggressive forms of breast cancer, such as triple negat
Autor:
CM Perou, Ian Hurley, Tatyana A. Grushko, O. I. Olopade, Galina Khramtsova, Ashley Hardeman, W Clayton, Joel S. Parker
Publikováno v:
Cancer Research. 79:P3-07
This abstract was not presented at the conference. Citation Format: Hardeman A, Grushko T, Clayton W, Hurley I, Khramtsova G, Parker J, Perou C, Olopade O. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 201
Autor:
Tatyana A. Grushko, Marsha A. Apushkin, Michael J. Birrer, Virginia L. Filiaci, Olufunmilayo I. Olopade, Carlton Schwab, Nilsa C. Ramirez, Laura Monovich, Shelly Seward, Maria J. Gomez, Joshua Kesterson, Gini F. Fleming, Michael W. Method, Anthony G. Montag
Publikováno v:
Appl Immunohistochem Mol Morphol
We performed a pilot study in anticipation of using long-aged precut formalin-fixed paraffin-embedded tissue sections stored in real-world conditions for translational biomarker studies of topoisomerase 2A (TOP2A), Ki67, and human epidermal growth fa
Autor:
Tatyana A. Grushko, Katherine B. Geiersbach, Patrick P. Bedroske, Kristine Jacobson, Yossi Avisror, Yishay Tauber, Vitaliy Shkolnik, Irina A. Sokolova, Amber Schneider, Katerina Pestova, Jesse S. Voss
Publikováno v:
Cancer Research. 80:4256-4256
Background: Biomarker testing in lung cancer is often limited by a lack of sufficient formalin fixed, paraffin embedded (FFPE) tissue for comprehensive genomic profiling. To promote personalized therapy for lung cancer, a multiplex FISH assay was dev
Autor:
Olufunmilayo I. Olopade, K.A. Mills, Tatyana A. Grushko, Iris L. Romero, Gini F. Fleming, Jessica Hunn, Mohammed Habis, Masha Kocherginsky, Jean A. Hurteau, Obiageli Ezewuiro
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 1, p e0147145 (2016)
PLoS ONE, Vol 11, Iss 1, p e0147145 (2016)
There is increasing evidence that metformin, a commonly used treatment for diabetes, might have the potential to be repurposed as an economical and safe cancer therapeutic. The aim of this study was to determine whether stage III-IV or recurrent endo
Autor:
Everett E. Vokes, Tanguy Y. Seiwert, Cesar A. Perez, Hunho Song, Ezra E.W. Cohen, Olufunmilayo I. Olopade, Mark Agulnik, Luis E. Raez, Elizabeth A. Blair, Kerstin M. Stenson, Tatyana A. Grushko, Allison Dekker
Publikováno v:
Oral Oncology. 48:887-892
Gefitinib has activity in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and skin toxicity has been postulated to be a predictor of response and improved outcome.This open-label, multi-institution, phase II study evaluate
Autor:
Anke Baum, Natalie R. Young, Jing Liu, Ashley Hardeman, Olufunmilayo I. Olopade, Christian Soneru, Tatyana A. Grushko, Flavio Solca, Ezra E.W. Cohen
Publikováno v:
Targeted oncology, vol 10, iss 4
Targeted Oncology
Targeted Oncology
Epidermal growth factor receptor (EGFR) inhibitors have demonstrated efficacy in squamous cell carcinoma of the head and neck (SCCHN). In addition to EGFR, other ErbB family members are expressed and activated in SCCHN. Afatinib is an ErbB family blo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e107e7d344c172714dc137babd456963
https://escholarship.org/uc/item/0td1d0k9
https://escholarship.org/uc/item/0td1d0k9